Healthcare and Surgical Robotics

Published October 18, 2026

Law checked through October 18, 2026.

Medical robotics requires separate analysis of the device, intended use, FDA pathway, clinical practice, data, and facility deployment. Not every hospital robot is a medical device. Surgical systems, patient-care devices, and ordinary delivery or cleaning robots can fall under different regimes. FDA clearance or approval does not establish that every use, clinician, cybersecurity practice, or Texas patient communication is legally sufficient. [1; 2; 3]

Intended use and classification

The medical-device inquiry begins with the FDCA definition and the product's intended use. A robot intended for diagnosis or treatment can raise device requirements different from a platform carrying linens. Advertising, instructions, functions, and proposed uses matter. The analysis should identify the actual device classification and applicable controls before selecting a pathway. [1]

Section 510(k) premarket notification and premarket approval are different processes. Part 807 Subpart E addresses notification where required; Part 814 addresses PMA. Exemptions, classification, changes, and the actual intended use require their own examination. It is inaccurate to describe every surgical robot as simply registered or every medical robot as requiring the same application. [2; 3]

Clinical and deployment responsibility

The health provider's practice, credentialing, training, and patient-care duties remain distinct from the manufacturer's device obligations. A system's approved or cleared use does not itself establish that a particular practitioner is trained or that a facility has appropriate emergency processes. The deployment should identify who controls instruments, who supervises, and how the procedure continues or stops after a fault.

TRAIGA requires specified disclosure when AI is used in relation to health care service or treatment, with timing and an emergency provision. The actual AI use and statutory text should be examined, while informed consent and other practice requirements remain separate. A robot's obvious appearance does not necessarily satisfy every required disclosure. [4, § 552.051]

Reporting, corrections, and maintenance

Part 803 imposes medical-device reporting duties according to actor and event. Manufacturer, importer, and device-user-facility duties differ. The actual seriousness, malfunction criteria, knowledge, and timing must be reviewed; an internal incident report is not automatically an FDA submission. [5]

Part 806 addresses reportable corrections and removals and related records. A software change or field service action should be evaluated for its actual regulatory significance. Calling a change routine maintenance does not decide the legal question if it corrects a risk covered by the regulation. Support contracts should facilitate prompt manufacturer and facility cooperation. [6]

Cybersecurity and connected devices

Covered cyber devices have statutory requirements under FDCA § 524B, including matters relating to vulnerability management, updates, and software components. FDA's February 2026 cybersecurity guidance provides recommendations and supersedes the identified June 2025 guidance. The statute and guidance should retain their different legal status. [7; 8]

The hospital and vendor should identify remote access, accounts, network dependencies, software support, safe patching, and incident response. A network outage or security containment can affect clinical availability, so the fallback process must be understood. Patient-data obligations, including applicable HIPAA roles and agreements, require a separate analysis of the entities and information involved. [9]

Draft surgical robotics guidance

FDA's September 2026 Robotically-Assisted Surgical Devices Premarket Submissions document is draft guidance, not for implementation. It identifies recommendations on nonclinical testing, clinical data, and labeling for the described systems. It should not be presented as an effective regulation or a final new clearance requirement. The agency lists a November 24, 2026 comment date. [10]

A manufacturer can use the draft to assess likely review questions while maintaining the actual legal basis for its current submission. A facility should not assume that all products described as surgical robots fall within every statement in the draft without reviewing scope.

Liability and procurement

Texas Chapter 82 and federal preemption require claim-specific treatment. Riegel addresses express preemption for the device and state-law claims before the Supreme Court, including its discussion of parallel requirements. It is not a blanket declaration that every FDA-regulated robot is immune from state claims. Clearance, PMA, device status, and the actual claim matter. [11; 12]

Procurement should address performance, training, service, consumables, updates, data, evidence access, support life, and transition. The purchaser should distinguish medical performance from ordinary facility logistics. An autonomous delivery robot working near patients can create accessibility, premises, privacy, and workplace questions even when it is not marketed as a medical device.